Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Clinical trial NCT03787992 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03787992
Sponsor: Allist Pharmaceuticals, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

Start date: 2019-05-30
Primary completion: 2021-09-15
Enrollment: 358

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.